Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
BeiGene to Present at Upcoming Investor Conferences
From BeiGene
Via Business Wire
BeiGene to Present Dynamic View of Development Programs for Hematologic Malignancies at 64th ASH Meeting
From BeiGene
Via Business Wire
BeiGene Receives European Commission Approval for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
From BeiGene
Via Business Wire
BeiGene Expands Reach of its Innovative BTK Inhibitor with Recent Regulatory Approvals in Latin America
From BeiGene
Via Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults With CLL
From BeiGene
Via Business Wire
BeiGene Announces Positive Topline Results from Final Progression-Free Survival Analysis of BRUKINSA® (zanubrutinib) Compared to IMBRUVICA® (ibrutinib) in Phase 3 Chronic Lymphocytic Leukemia (CLL) Trial
From BeiGene
Via Business Wire
NICE Recommends BeiGene’s BRUKINSA® (zanubrutinib) for Patients with Waldenström’s Macroglobulinemia who have had at Least One Treatment
From BeiGene
Via Business Wire
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with Marginal Zone Lymphoma
From BeiGene
Via Business Wire
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
From BeiGene
Via Business Wire
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
From BeiGene
Via Business Wire
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
From BeiGene
Via Business Wire
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
From BeiGene
Via Business Wire
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
From BeiGene
Via Business Wire
BeiGene Reports Second Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
From BeiGene
Via Business Wire
BeiGene Appoints Chan Lee as General Counsel
From BeiGene
Via Business Wire
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
From BeiGene
Via Business Wire
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From BeiGene
Via Business Wire
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
BeiGene Announces BRUKINSA™ (zanubrutinib) Is Approved in 50 Markets
From BeiGene
Via Business Wire
BeiGene Announces PDUFA Goal Date Extension for U.S. sNDA for BRUKINSA for the Treatment of CLL/SLL
From BeiGene
Via Business Wire
BeiGene Highlights Growing Portfolio and Pipeline Targeting Hematologic Malignancies at European Hematology Association 2022 Congress
From BeiGene
Via Business Wire
China NMPA Approves Tislelizumab for Recurrent or Metastatic Nasopharyngeal Cancer
From BeiGene
Via Business Wire
BeiGene to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
From BeiGene
Via Business Wire
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio
From BeiGene
Via Business Wire
BeiGene Strengthens European Presence With the Opening of Regional Office in Basel, Switzerland
From BeiGene, Ltd.
Via Business Wire
BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress
From BeiGene
Via Business Wire
BeiGene Reports First Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab) for Injection for Pediatric Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
From BeiGene
Via Business Wire
BeiGene Breaks Ground on New Manufacturing and Clinical R&D Center at the Princeton West Innovation Campus in New Jersey
From BeiGene
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.